Modification of acetaminophen to reduce liver toxicity and enhance drug efficacy
A high school student’s Regeneron Science Talent Search project—designing a modified form of acetaminophen that could reduce liver toxicity and improve pain relief—prompts both praise for her advanced chemistry work and skepticism about how much elite youth research depends on parental connections and lab access. Commenters dig into the underlying medicinal chemistry, questioning scalability and drug-likeness of the proposed molecule, while also debating the risks and benefits of acetaminophen versus opioids like morphine and fentanyl, and whether common OTC painkillers would pass today’s safety standards.
Perceptions of the Project & Student Achievement
- Many commenters are amazed by the sophistication of the work for a 17‑year‑old and say it’s at least master’s-level chemistry.
- Others temper this by noting she did not win the overall competition, and that many finalists are doing similarly advanced work in diverse fields.
- Several people describe mixed emotions: inspiration, but also feelings of personal inadequacy or “falling short,” prompting a side discussion about whether one must “leave a mark” on the world.
Access, Mentorship, and Fairness in Science Fairs
- Strong consensus that high-end science fairs are largely about access to labs, equipment, and expert mentorship.
- Multiple anecdotes: projects done in university labs under close guidance from senior scientists or relatives; students often come from highly academic families.
- Some argue this doesn’t diminish the students’ effort, but makes clear these are not solo “garage” projects.
- There’s debate over whether such fairs genuinely advance science or mainly function as college-admissions theater and career-building for organizers.
Technical Discussion of the Chemistry
- Chemists note the core is a four-step synthesis adding a protecting/functional group to acetaminophen, with an iridium-catalyzed key step.
- The modified compound is computationally predicted to bind TRPV1 and reduce liver toxicity, but commenters see no in vitro or in vivo validation yet.
- Questions raised:
- Are these steps scalable and economical for mass production?
- Why use silicon, given silicon-containing drugs are generally difficult and may violate Lipinski rules (too lipophilic)?
- Whether the molecule’s properties could be tuned (e.g., by additional polar groups).
Patents and Commercial Prospects
- Some ask if the sponsor has patented the molecule; responses say composition-of-matter patents don’t require efficacy data, but real value would hinge on biological results.
- Commenters speculate that if expensive, such a drug would target high‑risk patients rather than replace cheap generic acetaminophen.
Acetaminophen, Toxicity, and Alternatives
- Long subthread on how close therapeutic and toxic doses are, overdose frequency, and the grim nature of liver-failure deaths.
- Debate over whether acetaminophen should remain OTC, especially given widespread unintentional overdoses from combination products.
- Discussion of N‑acetylcysteine as an antidote and why it isn’t routinely co‑formulated (taste, side effects, and risk of encouraging higher dosing).
- Many compare its modest analgesic effect (especially for strong pain) to NSAIDs and opioids, with varied personal responses.
- Some mention emerging concerns about dementia risk and subtle psychological effects, versus known GI/cardiovascular risks of NSAIDs.
Pain Management, Morphine, and End‑of‑Life Care
- Several comments pivot to opioids: morphine’s role in palliative care, overdose risks via respiratory depression, and side effects like constipation and cognitive dulling.
- There’s brief discussion of fentanyl as a superior clinical analgesic but socially tainted by illicit use.
- Some ethical tension: whether escalating morphine at end of life mainly relieves patient suffering or also hastens death for the “benefit” of caregivers.